PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305)Roy M. Gulick, Kenneth H. Mayer, Ian Frank et al.|The Journal of Infectious Diseases|2016Cited by 47
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in WomenRoy M. Gulick, Kenneth H. Mayer, Timothy Wilkin et al.|Annals of Internal Medicine|2017Cited by 31
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)Ian McGowan, Marybeth McCauley, Ian Frank et al.|eScholarship (California Digital Library)|2020Cited by 28
Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentionsK. Rivet Amico, Adaora A. Adimora, Catalina Ramirez et al.|Journal of the International AIDS Society|2019Cited by 28
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSMIan McGowan, Roy M. Gulick, Timothy Wilkin et al.|AIDS|2018Cited by 19